Harnedy, PA,Parthsarathy, V,McLaughlin, CM,O'Keeffe, MB,Allsopp, PJ,McSorley, EM,O'Harte, FPM,FitzGerald, RJ

2018

January

Journal Of Functional Foods

Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties

Published

()

Blue whiting Protein hydrolysate Antidiabetic Functional food Amino acid analysis Peptide identification GLUCAGON-LIKE PEPTIDE-1 ANGIOTENSIN-CONVERTING ENZYME BREWERS SPENT GRAIN SALMON SALMO-SALAR BETA-CELL LINE WHEY-PROTEIN ANTIOXIDANT ACTIVITIES BIOACTIVE PROPERTIES INSULIN RESPONSES GLYCEMIC RESPONSE

40

137

145

A blue whiting (Micromesistius poutassou) protein hydrolysate generated using Alcalase 2.4L and Flavourzyme 500L and its simulated gastrointestinal digestion (SGID) sample was assessed for antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl peptidase-IV (DPP IV), the hydrolysates mediated insulin and glucagon-like peptide-1 (GLP-1) release from BRIN-BD11 and GLUTag cells, respectively. No significant difference was observed in insulinotropic and DPP-IV inhibitory activity following SGID, while GLP-1 secretion increased significantly (p < 0.01). SGID resulted in a significant increase in membrane potential, intracellular calcium and cyclic AMP concentration (p < 0.001) versus a glucose control, indicating that insulin secretion may be mediated by the X-ATP channel-dependent and the protein kinase A pathways. Additionally, acute (90-120 min) and persistent (4 h) glucose-lowering effects of the blue whiting hydrolysate were observed in normal healthy mice. These results demonstrate that the blue whiting protein hydrolysate had significant metabolic effects relevant to glucose control in vivo.

10.1016/j.jff.2017.10.045